Gyre Therapeutics
(NASDAQ) GYRE
Gyre Therapeutics Financials at a Glance
Market Cap
$650.16M
Revenue (TTM)
$116.59M
Net Income (TTM)
$5.03M
EPS (TTM)
$0.02
P/E Ratio
315.04
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Price
$7.11
Volume
1,689
Open
$7.05
Price
$7.11
Volume
1,689
Open
$7.05
Previous Close
$7.11
Daily Range
$6.94 - $7.12
52-Week Range
$6.11 - $11.78
Dividend
$0.00
Beta (Volatility)
1.05 (Average)
Price
$7.11
Volume
1,689
Open
$7.05
Previous Close
$7.11
Daily Range
$6.94 - $7.12
52-Week Range
$6.11 - $11.78
GYRE News
GYRE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Gyre Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
625
CEO
Ping Zhang, MBA
Website
www.gyretx.comHeadquarters
San Diego, CA 92130, US
GYRE Financials
Key Financial Metrics (TTM)
Gross Margin
95%
Operating Margin
10%
Net Income Margin
4%
Return on Equity
6%
Return on Capital
8%
Return on Assets
3%
Earnings Yield
0.32%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$650.16M
Shares Outstanding
91.31M
Volume
1.69K
Short Interest
0.00%
Avg. Volume
101.75K
Financials (TTM)
Gross Profit
$111.17M
Operating Income
$11.49M
EBITDA
$14.01M
Operating Cash Flow
$1.01M
Capital Expenditure
$1.19M
Free Cash Flow
$180.00K
Cash & ST Invst.
$52.42M
Total Debt
$939.00K
Gyre Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$37.20M
+33.4%
Gross Profit
$35.45M
+32.8%
Gross Margin
95.31%
N/A
Market Cap
$650.16M
N/A
Market Cap/Employee
$1.12M
N/A
Employees
579
N/A
Net Income
$1.72M
-1640.4%
EBITDA
$815.00K
-28.1%
Quarterly Fundamentals
Net Cash
$51.49M
+105.3%
Accounts Receivable
$36.95M
+26.7%
Inventory
$10.17M
+60.5%
Long Term Debt
$303.00K
-65.8%
Short Term Debt
$636.00K
-10.8%
Return on Assets
3.03%
N/A
Return on Invested Capital
7.77%
N/A
Free Cash Flow
$5.77M
-64.7%
Operating Cash Flow
$5.63M
-104.0%